Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-06-28

FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Isentress (raltegravir) from Merck Sharp & Dohme LLC, signaling an update to its labeling/indication for HIV-1 i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Isentress (Raltegravir)

Snippet

SUPPL AP for ISENTRESS (RALTEGRAVIR)